Year Founded
2015
Ownership
Private
Employees
~50
Therapeutic Areas
Infectious DiseasesNeurologyOphthalmologyOncology
Stage
Phase 2
Modalities
Small moleculeNanomedicine

Ashvattha Therapeutics General Information

Multiple Phase 2a trials showing positive results including reduced treatment burden in wet AMD/DME patients and successful COVID-19 treatment. Platform enables targeted delivery of drugs to diseased cells with demonstrated safety in human trials.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

migaldendranib
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Ashvattha Therapeutics's pipeline data

Book a demo

Key Partnerships

Johns Hopkins University

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Ashvattha Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCJan 13, 2025$50.0MCompletedPhase 2
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Ashvattha Therapeutics's complete valuation and funding history, request access »

Ashvattha Therapeutics Investors

Tribe Capital
Investor Type: Venture Capital
Holding: Minority
Natural Capital
Investor Type: Venture Capital
Holding: Minority
Social Capital
Investor Type: Venture Capital
Holding: Minority